Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Nat Neurosci ; 14(12): 1569-73, 2011 Oct 23.
Article in English | MEDLINE | ID: mdl-22019732

ABSTRACT

Quantitative trait locus mapping of chemical/inflammatory pain in the mouse identified the Avpr1a gene, which encodes the vasopressin-1A receptor (V1AR), as being responsible for strain-dependent pain sensitivity to formalin and capsaicin. A genetic association study in humans revealed the influence of a single nucleotide polymorphism (rs10877969) in AVPR1A on capsaicin pain levels, but only in male subjects reporting stress at the time of testing. The analgesic efficacy of the vasopressin analog desmopressin revealed a similar interaction between the drug and acute stress, as desmopressin inhibition of capsaicin pain was only observed in nonstressed subjects. Additional experiments in mice confirmed the male-specific interaction of V1AR and stress, leading to the conclusion that vasopressin activates endogenous analgesia mechanisms unless they have already been activated by stress. These findings represent, to the best of our knowledge, the first explicit demonstration of analgesic efficacy depending on the emotional state of the recipient, and illustrate the heuristic power of a bench-to-bedside-to-bench translational strategy.


Subject(s)
Analgesics/therapeutic use , Pain Threshold/drug effects , Pain/drug therapy , Pain/genetics , Pain/physiopathology , Vasopressins/therapeutic use , Animals , Animals, Newborn , Capsaicin/adverse effects , Deamino Arginine Vasopressin/therapeutic use , Disease Models, Animal , Female , Genetic Association Studies , Habituation, Psychophysiologic/drug effects , Habituation, Psychophysiologic/genetics , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Molecular Weight , Pain/chemically induced , Pain Measurement/drug effects , Pain Measurement/methods , Pain Threshold/physiology , Polymorphism, Single Nucleotide/genetics , Quantitative Trait Loci , Receptors, Vasopressin/deficiency , Receptors, Vasopressin/genetics , Sex Factors , Stress, Psychological/genetics , Stress, Psychological/physiopathology
2.
Prog Neurobiol ; 92(2): 151-83, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20558236

ABSTRACT

Bee venom injection as a therapy, like many other complementary and alternative medicine approaches, has been used for thousands of years to attempt to alleviate a range of diseases including arthritis. More recently, additional theraupeutic goals have been added to the list of diseases making this a critical time to evaluate the evidence for the beneficial and adverse effects of bee venom injection. Although reports of pain reduction (analgesic and antinociceptive) and anti-inflammatory effects of bee venom injection are accumulating in the literature, it is common knowledge that bee venom stings are painful and produce inflammation. In addition, a significant number of studies have been performed in the past decade highlighting that injection of bee venom and components of bee venom produce significant signs of pain or nociception, inflammation and many effects at multiple levels of immediate, acute and prolonged pain processes. This report reviews the extensive new data regarding the deleterious effects of bee venom injection in people and animals, our current understanding of the responsible underlying mechanisms and critical venom components, and provides a critical evaluation of reports of the beneficial effects of bee venom injection in people and animals and the proposed underlying mechanisms. Although further studies are required to make firm conclusions, therapeutic bee venom injection may be beneficial for some patients, but may also be harmful. This report highlights key patterns of results, critical shortcomings, and essential areas requiring further study.


Subject(s)
Bee Venoms/administration & dosage , Bee Venoms/adverse effects , Pain/drug therapy , Pain/etiology , Peptides/administration & dosage , Animals , Humans , Nociceptors/drug effects , Nociceptors/physiology , Pain/chemically induced , Peptides/adverse effects
3.
Brain Res ; 1001(1-2): 78-86, 2004 Mar 19.
Article in English | MEDLINE | ID: mdl-14972656

ABSTRACT

Behavioral, hormonal and neuronal responses to prolonged exposure to the volatile components of essential oil (EO) extracted from citrus lemon were investigated in male and female rats. Animals were exposed to the lemon essence for 2 weeks while in their cage. Anxiety was then determined with the elevated plus-maze apparatus while nociception was evaluated with a phasic thermal pain stimulus (plantar test) and with a chemical pain stimulus (formalin test). At the end of the experimental sessions, brain areas were dissected to measure beta-endorphin (beta-EP) concentrations in the hypothalamus and periaqueductal gray matter (PAG). Blood samples were collected to determine corticosterone plasma levels. In both sexes, prolonged EO exposure decreased the time spent in the open arms of the plus-maze apparatus. EO-exposed males and females showed higher thermal nociceptive thresholds than controls when tested with the plantar test apparatus. EO exposure induced female-specific decreases in formalin-induced pain behaviors during the formalin test. beta-EP concentrations in the hypothalamus and PAG were affected by EO. Corticosterone was lower in EO-exposed animals of both sexes than in their controls. These results suggest that long-term exposure to lemon EO can induce significant, at times sex-specific, changes in neuronal circuits involved in anxiety and pain.


Subject(s)
Citrus/chemistry , Hypothalamus/drug effects , Maze Learning/drug effects , Oils, Volatile/pharmacology , Pain Threshold/drug effects , Periaqueductal Gray/drug effects , beta-Endorphin/metabolism , Analysis of Variance , Animals , Behavior, Animal/drug effects , Corticosterone/blood , Female , Formaldehyde , Male , Motor Activity/drug effects , Pain Measurement/drug effects , Plant Oils/pharmacology , Rats , Reaction Time/drug effects , Sex Factors , Time
4.
Pain ; 84(1): 1-12, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10601667

ABSTRACT

Corticotropin-releasing factor (CRF) is a peptide that is released from the hypothalamus and in widespread areas of the brain following exposure to stressors. It is considered to be a mediator of many of the effects of stress, and its analgesic properties have been demonstrated in many studies. However, for primarily methodological reasons, the effects of CRF in the central nervous system have been neglected whereas the peripheral effects of CRF have been overemphasized. We present evidence that: (1) CRF can act at all levels of the neuraxis to produce analgesia; (2) the release of beta-endorphin does not explain the analgesia following intravenous or intracranial CRF administration; (3) inflammation must be present for local CRF to evoke analgesia and (4) the analgesic effects of CRF show specificity for prolonged pain. These findings suggest that CRF may have a significant role in chronic pain syndromes associated with hypothalamic-pituitary-adrenal axis abnormalities. Furthermore, CRF may represent a new class of analgesics that merits further study. Implications for the relationship between stress and pain are discussed.


Subject(s)
Analgesia , Brain/physiology , Corticotropin-Releasing Hormone/physiology , Pain/physiopathology , Animals , Brain/drug effects , Brain/physiopathology , Corticotropin-Releasing Hormone/pharmacology , Humans , Hypothalamus/physiology , Hypothalamus/physiopathology , beta-Endorphin/physiology
SELECTION OF CITATIONS
SEARCH DETAIL